Zobrazeno 1 - 10
of 306
pro vyhledávání: '"Christine M, Lovly"'
Autor:
Pooja Middha, Rohit Thummalapalli, Michael J. Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A. Bejan, Eduardo Cardenas, Christina J. Falcon, David M. Faleck, Princess Margaret Lung Group, Matthew A. Gubens, Scott Huntsman, Douglas B. Johnson, Linda Kachuri, Khaleeq Khan, Min Li, Christine M. Lovly, Megan H. Murray, Devalben Patel, Kristin Werking, Yaomin Xu, Luna Jia Zhan, Justin M. Balko, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn’s disease (CD) and ulcerative colitis (UC) predisposes t
Externí odkaz:
https://doaj.org/article/46e01ed1d0cc4b39bd52631c3a872a9b
Autor:
Aakash Desai, Christine M. Lovly
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Externí odkaz:
https://doaj.org/article/94637f1a55b84367ab04d0c1725380c4
Autor:
Zhenfang Du, Benjamin P. Brown, Soyeon Kim, Donna Ferguson, Dean C. Pavlick, Gowtham Jayakumaran, Ryma Benayed, Jean-Nicolas Gallant, Yun-Kai Zhang, Yingjun Yan, Monica Red-Brewer, Siraj M. Ali, Alexa B. Schrock, Ahmet Zehir, Marc Ladanyi, Adam W. Smith, Jens Meiler, Christine M. Lovly
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
An EGFR mutant with kinase domain duplication (EGFR-KDD) was previously identified in an index patient, but the functional and therapeutic implications remain unclear. Here, the authors show that KDD occurs in other ErbB receptors in multiple cancers
Externí odkaz:
https://doaj.org/article/b948db7f0a2649d5908bbadfe529545e
Autor:
Athanasios R Paliouras, Marta Buzzetti, Lei Shi, Ian J Donaldson, Peter Magee, Sudhakar Sahoo, Hui‐Sun Leong, Matteo Fassan, Matthew Carter, Gianpiero Di Leva, Matthew G Krebs, Fiona Blackhall, Christine M Lovly, Michela Garofalo
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 7, Pp 1-16 (2020)
Abstract A subset of lung adenocarcinomas is driven by the EML4‐ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to on‐target mutations or parallel pathwa
Externí odkaz:
https://doaj.org/article/6544b05e1c244d05b4afe550ea63b803
Autor:
Lavanya Sivapalan, Wade T. Iams, Zineb Belcaid, Susan C. Scott, Noushin Niknafs, Archana Balan, James R. White, Prasad Kopparapu, Christopher Cann, Blair V. Landon, Gavin Pereira, Victor E. Velculescu, Christine L. Hann, Christine M. Lovly, Valsamo Anagnostou
Publikováno v:
Clinical Cancer Research. :OF1-OF14
Purpose: Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis, calling for improved real-time noninvasive biomarkers of therapeutic response. Experimental Design: We performed targeted error-correction sequencing on 171 se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::513e58885b12014079a0fd6aed4019ec
https://doi.org/10.1158/1078-0432.ccr-22-2242
https://doi.org/10.1158/1078-0432.ccr-22-2242
Autor:
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:340-350
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy opt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a83660f7ba47623d490e51b0c7653ed9
https://doi.org/10.6004/jnccn.2023.0020
https://doi.org/10.6004/jnccn.2023.0020
Autor:
Aakash Desai, Christine M. Lovly
Publikováno v:
Translational Lung Cancer Research. 12:615-628
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3711a77981e869256b6f4396b020a09
https://doi.org/10.21037/tlcr-22-708
https://doi.org/10.21037/tlcr-22-708
Autor:
Jarrod T. Smith, BA, Aneri Balar, MD, Dhairya A. Lakhani, MD, Christien Kluwe, MD, PhD, Zhiguo Zhao, MS, Prasad Kopparapu, PhD, Karinna Almodovar, PhD, Anel Muterspaugh, MPH, CPH, Yingjun Yan, MS, Sally York, MD, PhD, Leora Horn, MD, MSc, Sanja Antic, MS, Caterina Bertucci, MPA, Tristan Shaffer, MS, Lauren Hodsdon, MPH, Kavita Garg, PhD, Seyed Ali Hosseini, MD, PhD, Lee Lim, PhD, Evan Osmundson, MD, PhD, Pierre P. Massion, MD, Christine M. Lovly, MD, PhD, Wade Iams, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100110- (2021)
Introduction: Blood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ctDNA mean variant allele fre
Externí odkaz:
https://doaj.org/article/30a2425056284f07b711aa00850a555d
Autor:
Wade T. Iams, MD, Prasad R. Kopparapu, PhD, Yingjun Yan, MS, Anel Muterspaugh, MPH, Zhiguo Zhao, MS, Heidi Chen, PhD, Christopher Cann, MD, Sally York, MD, PhD, Leora Horn, MD, MS, Kristin Ancell, MD, Kenneth Wyman, MD, Caterina Bertucci, MPA, Tristan Shaffer, MS, Lauren A. Hodsdon, MPH, Kavita Garg, PhD, Seyed Ali Hosseini, MD, PhD, Lee P. Lim, PhD, Christine M. Lovly, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100024- (2020)
Introduction: Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor of disease relapse and death a
Externí odkaz:
https://doaj.org/article/4458f029679347a28119d2847325d282
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
AbstractCOVID-19 infections are characterized by inflammation of the lungs and other organs that ranges from mild and asymptomatic to fulminant and fatal. Patients who are immunocompromised and those with cardiopulmonary comorbidities appear to be pa
Externí odkaz:
https://doaj.org/article/2bca214e831f4d10be642963b861f9d7